Standing Order
CRISPR Therapeutics AG

Dashboard

CRISPR Therapeutics AG

CRSPNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$5.4B
Price$55.7652w $36.95 – $76.78
Conviction4/ 5
Revenue (TTM)$13M
Revenue growth YoY-64.2%
P/E (trailing)—
Gross margin-1534.4%
Operating margin-3971.5%
Net margin-3368.7%
52w price change+50.9%
Next earningsNov 9, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 22
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease.

  • Sep 21
    Ownership changeSEC

    Form 4 insider transaction filing for CRSP

  • Sep 21
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Sep 18
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics Phase 1 trial NCT07491172 for CTX310 in refractory dyslipidemias begins recruiting.

  • Sep 15
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1 trial NCT07491172 evaluating CTX310 in refractory dyslipidemias; status recruiting.

  • Sep 9
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1 trial of CTX310 for refractory dyslipidemias (NCT07491172).

  • Aug 11
    Ownership changeSEC

    SEC Form 4 filing for insider ownership transaction at CRISPR Therapeutics AG.

  • Aug 11
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07758634) of CTX340 for hypertension; status recruiting as of 2026-08-11.

  • Aug 3
    Financial resultsSEC

    CRISPR Therapeutics AG filed 8-K with items 2.02 and 9.01 on 2026-08-03.

  • Jul 23
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1 safety trial of CTX310 for refractory dyslipidemias (NCT07491172).

  • Jul 22
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.

  • Jul 20
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1 safety trial NCT07491172 of CTX310 in refractory dyslipidemias (status: recruiting).

  • Jul 16
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics begins Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.

  • Jun 15
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.

  • Jun 9
    Ownership changeSEC

    Form 4 insider ownership filing

  • Jun 9
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 9
    Ownership changeSEC

    SEC Form 4 insider ownership transaction filing.

  • Jun 9
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 9
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 9
    Ownership changeSEC

    Form 4 insider transaction filing by CRISPR Therapeutics AG.

Not financial advice — research and opinion only. Disclosures